开胃理脾口服液治疗功能性消化不良(脾虚气滞型)疗效观察

[目的]评价开胃理脾口服液治疗脾虚气滞型功能性消化不良(FD)的临床疗效。[方法]49例功能性消化不良患者随机分成两组,治疗组24例,对照组25例,治疗组服用开胃理脾口服液,对照组服用开胃理脾丸。观察胃排空功能、中医证候疗效。[结果]开胃理脾口服液对改善脾虚气滞型功能性消化不良患者的胃排空功能具有较好疗效,具有统计学意义(P<0.05)。对改善临床症状特别是胃脘或脘腹胀满、胃脘疼痛、食欲不振、餐后早饱症状均有明显疗效,具有统计学意义(P<0.01)。但与开胃理脾丸临床疗效的比较无统计学意义,二者无差别,两组临床研究过程中均无不良反映发生。[结论]开胃理脾口服液对改善FD患者胃排空功能、改善临床症状方面具有较好的疗效。可作为FD脾虚气滞型患者的常用药物。

Clinical Efficacy Evaluation about Kaiweilipi Oral Liquid on Functional Dyspepsia with Spleen Deficiency and Qi Stagnation

[Objective] To evaluate the clinical efficacy of Kaiweilipi oral liquid treating spleen deficiency and qi stagnation functional dyspepsia.[Methods]49 patients were divided into two groups Randomly.The patients(n=24) in treatment group received Kaiweilipi oral liquid and patients(n=25) in control group received Kaiweilipi pill.Then,the efficacies of gastric emptying and TCM syndrome were observed.[Results]Kaiweilipi oral liquid can improve the gastric emptying of patients whose syndrome is spleen deficiency and qi stagnation with statistical significance(P<0.05).And it can also better the clinical syndromes such as gastrectasis and abdominal distension,abdominal pain,anorexia,early satiety especially with statistical significance(P<0.01).But the clinical efficacy of Kaiweilipi oral liquid and Kaiweilipi pill has no difference with comparison(P>0.05).Adverse events didn’t take place in either group during the trial.[Conclusion]Kaiweilipi oral liquid can improve the gastric emptying and better the clinical syndromes of the patients.It will be the common drugs for FD patients with spleen deficiency and qi stagnation.